Physician profile
Philip H Cross
NPI 1083666754
$14,429.06
in general payments reported to CMS, 2019-2025
44 companies · $1,864 in 2025
The $1,864 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,813 · 2020: $1,737 · 2021: $2,274 · 2022: $2,145 · 2023: $2,357 · 2024: $2,240 · 2025: $1,864.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,365 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,365.41 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,013.67 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $1,614.12 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,613.89 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $1,079.73 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,009.96 | 2019-2025 | Jardiance, Ofev, Tradjenta |
| Abbvie INC. | $883.24 | 2021-2025 | Ubrelvy, Vraylar |
| Bayer Healthcare Pharmaceuticals INC. | $758.36 | 2023-2025 | |
| Pfizer INC. | $606.04 | 2019-2025 | |
| Amarin Pharma, INC. | $525.03 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $449.10 | 2019-2023 | Vaxneuvance, Gardasil 9, Pneumovax 23 |
| Amgen INC. | $413.48 | 2019-2025 | Otezla, Repatha, Evenity |
| Sanofi-Aventis U.S. LLC | $368.87 | 2019-2022 | |
| Astellas Pharma US INC | $360.47 | 2019-2025 | Veozah, Myrbetriq |
| Janssen Pharmaceuticals, INC | $336.62 | 2019-2025 | Spravato |
| Xeris Pharmaceuticals, INC. | $320.96 | 2021-2024 | Gvoke Hypopen |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Cross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.